Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pharma Cosmetix Research LLC is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is handled by 1 distinct examiner, CAIN, JENNIFER LYNN, who is responsible for 1 busiest examiner pending action. All current activity is localized in 1 distinct art unit, showing a concentrated prosecution profile. With only 1 pending office action, the company's current USPTO engagement is highly specific.
CAIN, JENNIFER LYNN is the sole examiner reviewing the pending claims, making her individual examination style the primary factor in the portfolio's progress. The 1 distinct art unit involved confirms that the Biotechnology & Pharmaceuticals prosecution is not currently spread across different technical departments, which simplifies the management of the company's legal efforts. Practitioners should focus on the specific feedback provided in the 1 busiest examiner pending action. This concentration under 1 distinct examiner allows for a highly specialized and direct communication strategy during the prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAIN, JENNIFER LYNN | 1 | 45.0% | +70.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697046 | ENDOCANNABINOID MIMETIC AND ANTI-INFLAMMATORY COMPOUND CONTAINING COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | CAIN, JENNIFER LYNN | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697046 | ENDOCANNABINOID MIMETIC AND ANTI-INFLAMMATORY COMPOUND CONTAINING COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | CAIN, JENNIFER LYNN | 70d |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17697046 | ENDOCANNABINOID MIMETIC AND ANTI-INFLAMMATORY COMPOUND CONTAINING COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | CAIN, JENNIFER LYNN | 1655 | §101§102§112 | Final Rejection | 70d | Pending | Mar 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial